Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Verrica Pharmaceuticals Q4 EPS $(0.53), Inline, Sales $1.99M Beat $910.00K Estimate

Author: Benzinga Newsdesk | February 29, 2024 08:34am
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. This is a 278.57 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.99 million which beat the analyst consensus estimate of $910.00 thousand by 118.46 percent. This is a 2.82K percent increase over sales of $68.00 thousand the same period last year.

Posted In: VRCA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist